IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/28/2026 03:24 PDT] IGC Are Seasonally Ripe To Go Down In the Next Five Weeks
• [05/28/2026 03:24 PDT] IGC Are Seasonally Ripe To Go Down In the Next Five Weeks
• [05/08/2026 07:10 PDT] IGC Expected to Trade Up After Bullish Patterns Develop
• [04/22/2026 04:00 PDT] IGC Expected to Trade Down After Bearish Patterns Develop